Literature DB >> 27995636

Managing the Rising Costs and High Drug Expenditures in Critical Care Pharmacy Practice.

Alexander H Flannery1,2, Komal Pandya1,2, Melanie E Laine1, Philip J Almeter1, Jeremy D Flynn1,2.   

Abstract

Pharmaceutical costs for patients in the intensive care unit (ICU) constitute a large portion of hospital drug budgets. Unfortunately, prices for medications commonly used in the ICU are on the rise for a variety of reasons. In particular, the U.S. Food and Drug Administration's Unapproved Drugs Initiative, generic manufacturers cornering the marketplace, drug shortages, and regulatory device changes are major drivers of pharmaceutical price escalation affecting costs in the ICU. Furthermore, traditional high acquisition cost items still pose challenges to controlling costs. To offer strategies to mitigate the rising costs of pharmaceuticals in the ICU setting, we searched the PubMed/Medline and International Pharmaceutical Abstracts databases and other related sources to identify published cost-saving protocols concerning specific medications that are affected by rising prices or have traditional high acquisition costs. In the absence of specific protocols, we offer possible cost-saving initiatives based on published literature regarding specific agents or based on our own diverse set of experiences. Finally, we review suggested clinical and operational activities at an institutional level to address these rising drug costs in the ICU setting.
© 2016 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  cost; cost savings; critical care; medication

Mesh:

Substances:

Year:  2016        PMID: 27995636     DOI: 10.1002/phar.1862

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Impact of Implementing Smart Infusion Pumps in an Intensive Care Unit in Mexico: A Pre-Post Cost Analysis Based on Intravenous Solutions Consumption.

Authors:  Erika Palacios Rosas; Isaac F Soria-Cedillo; Fabiola Puértolas-Balint; Rebecca Ibarra-Pérez; Sergio E Zamora-Gómez; Elizabeth Lozano-Cruz; Marcos A Amezcua-Gutiérrez; Lucila I Castro-Pastrana
Journal:  Hosp Pharm       Date:  2018-07-11

2.  Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.

Authors:  Mina Tadrous; Diana Martins; Muhammad M Mamdani; Tara Gomes
Journal:  CMAJ Open       Date:  2020-04-28

3.  Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis.

Authors:  Mina Tadrous; Benjamin Daniels; Sallie-Anne Pearson; Tara Gomes
Journal:  CMAJ Open       Date:  2021-11-23

4.  Explaining the consequences of missed nursing care from the perspective of nurses: a qualitative descriptive study in Iran.

Authors:  Maryam Janatolmakan; Alireza Khatony
Journal:  BMC Nurs       Date:  2022-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.